Wed, Aug 20, 2014, 7:23 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • nopseudonym nopseudonym Sep 27, 2012 12:56 AM Flag

    diabetic nephropathy

    I think its quite interesting that Lilly is testing baricitinib for diabetic nephropathy.. If this indication pans out, it would underscore how versatile JAK inhibitors are. It seems to be a pretty large unmet need.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This is one of many instances where several cytokine pathways are involved in causing harm. A single inhibitor may or may not do much good (best f'rinstance is aspirin, which turns the double-edged eicosanoid family mostly anti-inflamatory). Another interesting possibility is "classic" interferon inhibition, which is of unknown safety, but pretty much cures the common cold. ANYway, if you have a bunch of money and time, and have a well-tolerated inhibitor of a relatively-little-investigated cytokine pathway, it makes sense to do some testing in conditions where that kind of mechanism is active (and really, that's the situation in RA, too: COX-2 inhibition helps, TNF inhibition helps, inhibition of cellular attack helps and now JAK inhibition helps. So far, combinations have given modest therapeutic benefit with much worse side effects, but that may not always happen)

51.66-0.46(-0.88%)Aug 20 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.